A securities fraud class action has been filed against GRAIL, Inc. and certain senior executives following a 50.55% stock drop on February 20, 2026. The lawsuit, pending in the U.S. District Court for the Northern District of California, alleges that GRAIL made misleading positive statements about its NHS-Galleri cancer screening trial, including that the three-year trial design was sufficient to achieve the primary endpoint of reducing late-stage cancers. On February 19, 2026, GRAIL disclosed that the trial did not meet that endpoint, attributing the shortfall partly to a need for longer follow-up, which caused shares to fall from $101.53 to $50.21. Investors have until August 4, 2026 to seek lead plaintiff appointment.
GRAIL, LLCSecurities fraud class action lawsuit filed after trial missed primary endpoint, causing 50.55% stock drop.